Search results for "Immunologic"

showing 10 items of 1115 documents

Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization

2015

Imiquimod, a toll-like receptor 7 (TLR7) agonist, is an active pharmaceutical ingredient (API) established for the topical treatment of several dermal cancerous and precancerous skin lesions. Within this work, the immunostimulatory effect of imiquimod is further exploited in a transcutaneous immunization (TCI) approach based on a solid nanoemulsion (SN) formulation. SN contains a combination of imiquimod with the model peptide antigen SIINFEKL as a novel approach to omit needle and syringe and optimize dermal antigen administration. Excipients including sucrose fatty acid esters and the pharmaceutically acceptable oils MCT (middle chain triglycerides), avocado oil, jojoba wax and squalene a…

0301 basic medicineSkin NeoplasmsChemistry PharmaceuticalImmunologyAntineoplastic AgentsImiquimodImmunopotentiatorBiologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health sciencesFreeze-dryingSqualenechemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAdjuvants ImmunologicAntigenIn vivomedicineAnimalsHumansActive ingredientImiquimodChromatographyVaccinationPermeationNanostructuresMice Inbred C57BL030104 developmental biologychemistryLangerhans CellsImmunologyAminoquinolinesImmunizationOilsPrecancerous Conditionsmedicine.drugCellular Immunology
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a rando…

2019

PMC6682346; Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naive hepatocellular carcinoma (HCC) demonstrated an overall survival (OS) benefit. This randomized, open-label Phase IIb trial investigated whether Pexa-Vec plus Best Supportive Care (BSC) improved OS over BSC alone in HCC patients who failed sorafenib therapy (TRAVERSE). 129 patients were randomly assigned 2:1 to Pexa-Vec plus BSC vs. BSC alone. Pexa-Vec was given as a single intravenous (IV) infusion fol…

0301 basic medicineSorafenibOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyHepatocellular carcinomamedicine.medical_treatmentImmunologyPexastimogene-devacirepvecAucunSciences du Vivant [q-bio]/Médecine humaine et pathologielcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigenInternal medicinemedicineClinical endpointImmunology and AllergyHepatocellular carcinoma; oncolytic immunotherapy; oncolytic vaccinia; Pexa-Vec; sorafeniboncolytic vacciniaOriginal Researchbusiness.industryImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncolytic virus030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaPexa-Veconcolytic immunotherapysorafenibVacciniabusinesslcsh:RC581-607[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Comparative study of the production of soluble factors in human placenta-derived mesenchymal stromal/stem cells grown in adherent conditions or as ag…

2019

Abstract Different approaches have been studied in both preclinical and clinical settings to develop cell-based therapies and/or engineered cell-based therapies to better integrate grafts with the host. In these techniques, much attention is addressed to the use of adult stem cells such as mesenchymal stem cells (MSCs), but identifying and obtaining sufficient numbers of therapeutic cells, and the right route of administration, is often a challenge. In this study, we tested the feasibility of encapsulating human amnion-derived MSCs (hAMSCs) in a semipermeable and biocompatible fiber as a new approach for regenerative medicine. Our data showed that hAMSCs aggregated in the device constitutes…

0301 basic medicineStromal cellAngiogenesisCell SurvivalPlacentaCellBiophysicsCell Culture TechniquesBiocompatible MaterialsBiologyParacrine effectsBiochemistryRegenerative medicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemCell MovementPregnancymedicineCell AdhesionHuman Umbilical Vein Endothelial CellsHumansImmunologic FactorsAmnionMolecular BiologyCell AggregationSettore MED/04 - Patologia GeneraleCatheter-like devicePlacenta-derived stromal/stem cellsSettore BIO/16 - Anatomia UmanaMesenchymal stem cellMesenchymal Stem CellsCell BiologyCells Immobilized030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisRegenerative medicineCancer researchAngiogenesis Inducing AgentsFemaleAngiogenesisStem cellAdult stem cell
researchProduct

Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma

2018

Since the proper activation of T cells requires the physical interaction with target cells through the formation of immunological synapses (IS), an alteration at this level could be a reason why tumors escape the immune response. As part of their life cycle, it is thought that T cells alternate between a static phase, the IS, and a dynamic phase, the immunological kinapse (IK), depending on high or low antigen sensing. Our investigation performed in tissue samples of human glioma shows that T cells are able to establish synapsing interactions not only with glioma tumorigenic cells, but also with stromal myeloid cells. Particularly, the IS displaying a T cell receptor-rich (TCR-rich) central…

0301 basic medicineStromal cellCD3 ComplexImmunological SynapsesT-LymphocytesT cellAntigen-Presenting CellsImmunological synapse03 medical and health sciencesImaging Three-DimensionalImmune systemAntigenGliomaTumor MicroenvironmentmedicineHumansMyeloid CellsBrain NeoplasmsChemistryGliomaGeneral Medicinemedicine.diseaseImmunological SynapsesCell biology030104 developmental biologymedicine.anatomical_structureTechnical AdvanceTumor EscapeTumor EscapeGlioblastomaJCI Insight
researchProduct

Parallels and differences between innate and adaptive lymphocytes.

2016

Lymphocytes are essential in innate and adaptive immunity. Recent insights suggest that some innate lymphocytes execute functions with adaptive characteristics, while adaptive lymphocytes can operate in ways reminiscent of innate cells. Rather than partitioning lymphocytes according to the type of effector function they execute, we propose that a relevant discrimination relates to the existence of conventional T cells in a naive state. The naive state can be seen as an actively repressed condition that supports T cell diversity and enables the flexible differentiation of effector cells in a manner that best addresses the antigenic challenge. We discuss these considerations in the context of…

0301 basic medicineT cellImmunologyContext (language use)BiologyAdaptive Immunity03 medical and health sciencesImmune systemAntigenImmunitymedicineImmunology and AllergyAnimalsHumansLymphocytesEffectorInnate lymphoid cellModels ImmunologicalCell DifferentiationAcquired immune systemImmunity InnateClone CellsReceptors Antigen030104 developmental biologymedicine.anatomical_structureImmunologyCytokinesNeuroscienceNature immunology
researchProduct

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

2019

Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no identified characteristics in the diagnosis of MGUS that have been helpful in differentiating subjects whose cancer may progress to a malignant situation. Regarding malignancy, the role of lymphocyte subsets and cytokines at the beginning of neoplastic diseases is now incontestable. In this review, we have concentrated our attention on the equilibrium between the diverse lymphocyte subsets and the cytokine system and summarized the current state of knowledge, providing an overview of the condition of the entire system in …

0301 basic medicineT lymphocytesimmunosurveillanceReviewMalignancyMonoclonal Gammopathy of Undetermined SignificanceCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineImmune systemSettore MED/43 - Medicina LegaleMonitoring ImmunologicGammopathycytokineMedicineHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyMultiple myelomamonoclonal gammopathy of undetermined significance; multiple myeloma; T lymphocytes; cytokine; alarmin; inflammation; immunosurveillancebusiness.industryOrganic ChemistryCancerGeneral Medicinealarminmedicine.diseaseLymphocyte SubsetsComputer Science ApplicationsImmunosurveillancemultiple myeloma030104 developmental biologylcsh:Biology (General)lcsh:QD1-999inflammation030220 oncology & carcinogenesisImmunologyMonoclonalCytokinesbusinessMonoclonal gammopathy of undetermined significance
researchProduct

Guidelines for the use of flow cytometry and cell sorting in immunological studies

2017

The marriage between immunology and cytometry is one of the most stable and productive in the recent history of science. A rapid search in PubMed shows that, as of July 2017, using “flow cytometry immunology” as a search term yields more than 68 000 articles, the first of which, interestingly, is not about lymphocytes. It might be stated that, after a short engagement, the exchange of the wedding rings between immunology and cytometry officially occurred when the idea to link fluorochromes to monoclonal antibodies came about. After this, recognizing different types of cells became relatively easy and feasible not only by using a simple fluorescence microscope, but also by a complex and some…

0301 basic medicineT-LymphocytesCell SeparationT cell precursors0302 clinical medicineImmunophenotypingHuman lymphopoiesis[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyImmunology and AllergyNon-U.S. Gov'tImmunologic Techniquemedicine.diagnostic_testResearch Support Non-U.S. Gov'tvirus diseaseshemic and immune systemsFalse Positive ReactionCell sortingFlow Cytometrynatural killer and innate lymphoid cells differentiation3. Good healthResearch Design[SDV.IMM]Life Sciences [q-bio]/ImmunologyHumanQuality Controlmedicine.drug_classImmunologyAnimals; Cell Proliferation; Cell Separation; DNA; False Positive Reactions; Flow Cytometry; Humans; Immunophenotyping; Quality Control; RNA; Research Design; Software; T-Lymphocytes; Guidelines as Topic; Immunologic Techniques; Immunology and Allergy; Immunologychemical and pharmacologic phenomenaGuidelines as TopicComputational biologyBiologyMonoclonal antibodyResearch SupportArticleFlow cytometryImmunophenotypingN.I.H.03 medical and health sciencesImmune systemImmunologic TechniqueResearch Support N.I.H. Extramuralmedicineearly lymphoid progenitorsJournal ArticleAnimalsHumansMass cytometryFalse Positive ReactionsImmunology and Allergy; Immunology; Flow cytometryIMUNOLOGIACell ProliferationAnimalExtramuralB cell ontogenyDNA030104 developmental biologyT-LymphocyteImmunologic TechniquesRNACytometrySoftware030215 immunologyEuropean Journal of Immunology
researchProduct

Combined B, T and NK Cell Deficiency Accelerates Atherosclerosis in BALB/c Mice.

2016

This study focused on the unique properties of both the Ldlr knockout defect (closely mimicking the human situation) and the BALB/c (C) inbred mouse strain (Th-2 slanted immune response). We generated two immunodeficient strains with severe combined B- and T-cell immunodeficiency with or without a complete lack of natural killer cells to revisit the role of adaptive immune responses on atherogenesis. C-Ldlr-/- Rag1-/- mice, which show severe combined B- and T-cell immunodeficiency and C-Ldlr-/- Rag1-/- Il2rg-/- mice, which combine the T- and B-cell defect with a complete lack of natural killer cells and inactivation of multiple cytokine signalling pathways were fed an atherogenic Western ty…

0301 basic medicineT-Lymphocyteslcsh:MedicineNK cellsAdaptive ImmunityBiochemistryVascular MedicineMicechemistry.chemical_compoundCellular typesReceptorlcsh:ScienceImmunodeficiencyMice KnockoutB-LymphocytesMice Inbred BALB CMultidisciplinarybiologyT CellsImmune cellsAcquired immune systemLipidsPlaque AtheroscleroticKiller Cells NaturalCholesterolPhenotypeWhite blood cellsFemalelipids (amino acids peptides and proteins)Research ArticleCell biologyBlood cellsLipoproteinsImmunologyResearch and Analysis MethodsBALB/cImmune Deficiency03 medical and health sciencesImmune systemmedicineAnimalsImmunohistochemistry TechniquesTriglyceridesMedicine and health sciencesBiology and life sciencesCholesterolMacrophageslcsh:RImmunologic Deficiency SyndromesWild typeProteinsAtherosclerosisbiology.organism_classificationmedicine.diseaseMolecular biologyHistochemistry and Cytochemistry Techniques030104 developmental biologyAnimal cellsReceptors LDLchemistryImmune SystemMutationImmunologyLDL receptorImmunologic TechniquesClinical Immunologylcsh:QClinical MedicinePLoS ONE
researchProduct

Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery

2020

Successful outcome of immune checkpoint blockade in patients with solid cancers is in part associated with a high tumor mutational burden (TMB) and the recognition of private neoantigens by T-cells. The quality and quantity of target recognition is determined by the repertoire of ‘neoepitope’-specific T-cell receptors (TCRs) in tumor-infiltrating lymphocytes (TIL), or peripheral T-cells. Interferon gamma (IFN-γ), produced by T-cells and other immune cells, is essential for controlling proliferation of transformed cells, induction of apoptosis and enhancing human leukocyte antigen (HLA) expression, thereby increasing immunogenicity of cancer cells. TCR αβ-dependent therapies should account f…

0301 basic medicineT-Lymphocytesmedicine.medical_treatmentprecision medicineImmunologyEpitopes T-LymphocyteReviewHuman leukocyte antigenBiologyMajor histocompatibility complexCancer Vaccines03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemAntigenAntigens NeoplasmantigensNeoplasmsmedicineAnimalsHumansImmunology and AllergyT-cell receptorTumor microenvironmentneoepitopesWhole Genome SequencingT-cellsT-cell receptorComputational BiologyImmunotherapyTILRC581-607vaccinationImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinimmunotherapyImmunologic diseases. AllergyFrontiers in Immunology
researchProduct